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Staphylococcus simulans biovar staphylolyticus lysostaphin efficiently cleaves
Staphylococcus aureus cell walls. The protein is in late clinical trials as a
topical anti-staphylococcal agent, and can be used to prevent staphylococcal
growth on artificial surfaces. Moreover, the gene has been both stably engi-
neered into and virally delivered to mice or livestock to obtain resistance
against staphylococci. Here, we report the first crystal structure of mature
lysostaphin and two structures of its isolated catalytic domain at 3.5, 1.78
and 1.26 A resolution, respectively. The structure of the mature active
enzyme confirms its expected organization into catalytic and cell-wall-tar-
geting domains. It also indicates that the domains are mobile with respect
to each other because of the presence of a highly flexible peptide linker. The
high-resolution structures of the catalytic domain provide details of Zn2+
coordination and may serve as a starting point for the engineering of lyso-
staphin variants with improved biotechnological characteristics.
Structured digital abstract
• lysostaphin by x-ray crystallography (1, 2).
Introduction
Staphylococcus aureus is a common human and animal
pathogen of major clinical significance [1]. Staphylococ-
cus simulans lysostaphin (EC 3.4.24.75) has staphylolyt-
ic properties that were originally discovered in the 1960s
[2,3] and immediately attracted interest as a means of
combating staphylococcal infection [4]. The topical or
systemic use of lysostaphin has since proven effective in
several mouse and rat models of staphylococcal infec-
tion [5,6]. Moreover, transgenic mice and cattle produc-
ing the enzyme have been generated to engineer
S. aureus and/or S. epidermidis resistance [7,8], and ade-
novirus-mediated lysostaphin delivery has been tested in
goats [9,10]. In humans, the protein has been effective in
the experimental treatment of S. aureus-infected
patients [11], and is currently in clinical trials for use in
treating burns [12]. Lysostaphin has also shown promise
for the elimination of S. aureus in infected asymptom-
atic carriers [13], which might be useful in a hospital set-
ting. Apart from direct application in humans,
lysostaphin has also been considered for the eradication
of S. aureus biofilms from artificial surfaces [14] and as
an antimicrobial agent in catheter coatings [15].
Lysostaphin is produced as a preproprotein (Uni-
Prot entry P10547) with a leader sequence (residues
Abbreviations
CWT, cell-wall-targeting domain; MAD, multiple anomalous diffraction; MR, molecular replacement.
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1–23), inhibitory proregion (residues 24–247) [16],
catalytic domain (residues 248–384), linker (residues
385–400) and cell-wall-targeting (CWT) domain (resi-
dues 401–493, UniProt numbering used throughout)
(Fig. 1A). The latter three constitute the mature pepti-
dase, henceforth termed ‘lysostaphin’. This cuts the
peptide bond between the third and fourth glycine resi-
dues of the pentaglycine cross-link in the peptidogly-
can (Fig. 1B) [17]. The active enzyme shares
structurally characterized domains with LytM [18,19],
Ale-1 [20] and LasA [21], but only the structure of
mature lysostaphin can shed light on crucial aspects of
the domain arrangement or substrate binding of this
biotechnologically important enzyme.
Lysostaphin has many favorable properties (e.g.
dependence of the enzyme activity on the ionic milieu
compatible with in vivo applications) that are not shared
by some of its homologues [22]. However, widespread
use of lysostaphin has also identified its limitations.
Staphylococcus aureus cells can acquire lysostaphin
resistance by altering cross-bridges between peptidogly-
can stem peptides [23]. A structure of lysostaphin might,
therefore, be helpful in understanding its favorable
properties, which could then be grafted onto homo-
logues that do not share them (such as LytM [22]), as
well as being used to generate variants of lysostaphin
that overcome the limitations of the natural enzyme.
A crystal structure of lysostaphin has not yet been
reported, despite widespread interest in the protein
and the possible applicability of structural informa-
tion. Here, we present a low-resolution (3.5 A) struc-
ture of mature lysostaphin with catalytic and CWT
domains, and two high-resolution (1.26 and 1.78 A)
crystal structures of the catalytic domain in isolation,
which elucidate details of the active site architecture.
Results and discussion
Crystallization and structure determination of
mature lysostaphin
Several differently tagged variants of mature lysosta-
phin (with catalytic and CWT domains, but without
the proregion and leader peptide) were produced in
the ectopic host Escherichia coli and purified by affin-
ity chromatography and gel-filtration steps. The pro-
tein proved difficult to crystallize. Altogether, over
10 000 possible conditions were screened until diffract-
ing crystals were obtained. Crystals diffracted to 3.5 A
and belonged to space group P4(3)32 with a large unit
cell (282 A length). Nevertheless, they contained only
four molecules of lysostaphin in the asymmetric unit,
which corresponds to > 85% solvent content (observed
for only 0.05% of other crystals in the PDB). In retro-
spect, the large solvent content can be attributed to a
highly unusual crystal packing. Although lysostaphin
is a monomer in solution [24], pairs of lysostaphin
molecules (adopting different conformations) assemble
to form ‘heterodimers’. Because of a combination of
local and crystallographic twofold symmetry, the origi-
nal ‘heterodimers’ in turn form hollow, ball-like struc-
tures with 222-point symmetry, built of eight
lysostaphin molecules (Fig. 2A). Although balls can,
in principle, be packed very tightly (74% of space
filled [25]), the assembly of balls in the lysostaphin
crystals is characterized by large pores that are clearly
visible in projections along the unit cell axes (Fig. 2B)
and along the body diagonals (not shown). The phase
problem for crystals of mature lysostaphin was solved
using a combination of molecular replacement (search
models based on deposited crystal structures of
A B
Fig. 1. Domain organization of lysostaphin and related enzymes. Blue and red bars (labelled by PDB accession codes) indicate fragments
structurally characterized earlier and in this work, respectively. Gray colors are used for regions of unknown structure.
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catalytic domain of LytM and CWT domain of Ale-1,
respectively) and multiple anomalous diffraction
(MAD) approaches. Data collection and refinement
parameters are presented in Table 1.
Because multiple attempts to improve the diffraction
limit of the mature lysostaphin crystals at synchrotrons
(using annealing, dehydration, etc.) proved unsuccess-
ful, we produced the catalytic domain in isolation,
hoping that the globular nature of the domain would
facilitate crystal packing. Indeed, crystals in space
group P2(1) could be grown at similar pH in the pres-
ence and absence of phosphate. They diffracted to
1.26 and 1.78 A resolution, respectively. The strongest
diffracting crystals were pseudomerohedrally twinned
[26] with a twofold twinning axis along a face diago-
nal, made possible by the ‘coincidental’ equality of
unit cell constants. Both structures could be readily
solved by molecular replacement. For refinement, test
reflections were chosen in thin-resolution shells to
avoid introducing correlations between reflections.
Data collection and refinement statistics for both
structures are summarized in Table 1.
Overall lysostaphin structure
The crystal structure shows the expected overall orga-
nization of lysostaphin into an N-terminal catalytic
domain and a C-terminal CWT domain (Fig. 3). When
superimposed separately, the domains of the four mol-
ecules in the asymmetric unit of the mature lysosta-
phin crystals overlap very well, which may in part
reflect the use of noncrystallographic symmetry
restraints necessary at this resolution. However, we
also observe essentially the same conformation in the
crystals of the catalytic domain in isolation, suggesting
that, at least, the structure of this domain is robust to
changes in buffer composition. Amino acid conserva-
tion scores among selected sequences of catalytic and
CWT domains from various Staphylococci and their
bacteriophages, showing up to 45% sequence identity
to lysostaphin were mapped to the surface of its
domains and are high in the region of the active site,
and also in the likely peptide-binding region of the
CWT domain (Fig. 4A,B). The electrostatic surface of
lysostaphin is a meshwork of regions of positive and
negative potential, without large hydrophobic regions,
consistent with either solvent exposure or binding to
the pentaglycine peptide (containing multiple hydrogen
bond donors and acceptors) (Fig. 4C).
Catalytic domain
The lysostaphin catalytic domain shares key features
of the M23 family peptidases [27]. The core of these
structures is an antiparallel b sheet that anchors the
catalytic residues, which are grouped around a central
Zn2+ cation (Fig. 5). Identification of this metal ion
was confirmed crystallographically (by a drop in the
anomalous density peak height at the metal ion sites
passing from the absorption to the inflection point
wavelength). In the high-resolution structures it is
additionally supported by typical metal–ligand dis-
tances and similar temperature factors for the metal
ion and the surrounding ligands. The Zn2+ ion is
coordinated by His279 and Asp283 of the characteris-
tic HxxxD motif and His362 of the HxH motif of
LAS peptidases, as expected.
A B
Fig. 2. Crystal structure of mature lysostaphin. (A) Four
crystallographically independent lysostaphin molecules (ribbon
models) and their symmetry mates (behind them) form a hollow
‘ball’ of 222 point symmetry composed of altogether eight
lysostaphin molecules (gray). The twofold symmetry axes are
indicated as lines. (B) Packing of the ‘balls’ in (A) into the crystal
lattice. The ‘face’ of the ball presented in (A) is turned towards the
lower right-hand corner in (B).
Fig. 3. Domain mobility in full-length lysostaphin. Molecules in the
asymmetric unit of the crystal are shown in ribbon representation,
with the catalytic zinc ion shown as a ball. CWT (green) domains
were superimposed. Catalytic domains (dark/light yellow and blue)
differ in orientation by almost 100°.
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The active site is located in a substrate-binding
groove, as in other MEROPS M23 family proteins.
The floor of the groove is built by the b sheet of the
protein and the walls are made up of loops L1–L4 as
defined previously for LasA [21] and LytM [19]. The
long L-shaped loop 1 is located above the Zn2+ ion
Table 1. Data collection and refinement statistics
Data collection statistics
Full-length lysostaphin
Catalytic domain
MAD peak MAD IP Nativea
Space group P4(3)32 P4(3)32 P4(3)32 P2(1) P2(1)
Cell dimensions
a (A) 283.6 283.3 282.0 34.3 34.3
b (A) 106.8 107.3
c (A) 34.3 34.3
b (°) 97.4 97.6
Beamline DIAMOND IO2 BESSY 14.1 BESSY 14.1 BESSY 14.2
Wavelength (A) 1.2827 1.2832 0.9184 1.2000 0.9184
Resolution (A) 35–4.0 35–4.0 50–3.5 50–1.26 35–1.78
Lowest shell 35–17.85 35–17.84 50–15.65 50–3.76 35–5.28
Highest shell 4.09–3.99 4.09–3.99 3.59–3.5 1.33–1.26 1.89–1.78
Rsym (%)
b 28.5 (6.5, 54.2) 14.7 (3.2, 49.0) 29.5 (5.1, 90.8) 7.2 (5.6, 41.2) 16.7 (5.7, 58.6)
Rmeas (%)
b 34.2 (7.8, 65.7) 17.6 (3.8, 58.9) 30.0 (5.2, 92.0) 7.8 (6.1, 46.6) 21.3 (7.3, 73.0)
CC1/2
b 93.8 (98.8, 77.7) 98.2 (99.8, 82.3) 99.6 (100, 94.4) 99.8 (99.7, 84.8) 96.6 (99.1, 68.6)
I/rIb 5.6 (12.1, 2.8) 8.0 (18.5, 3.5) 17.3 (57.0, 5.3) 13.2 (30.8, 2.5) 7.5 (17.0, 2.1)
Completeness (%)b 96.3 (82.6, 97.8) 98.7 (82.3, 98.7) 100.0 (100, 95.5) 98.3 (99.8, 90.9) 99.1 (97.1, 98.8)
Multiplicityb 3.17 (3.30, 3.11) 3.22 (3.29, 3.22) 36.4 (28.9, 37.9) 5.8 (6.3, 4.5) 2.7 (2.7, 2.7)
VM 8.3 2.0 2.0
Solvent content (%) 85.2 39.6 39.9
Twin law l,-k,h (l,-k,h)d
Twin fraction (%)
Estimated 37 22
Refined 36.0 –
<|E2  1|> 0.758 0.776 0.746 0.622 0.700
<|L|>, <L2> 0.468, 0.296 0.493, 0.323 0.488, 0.317 0.409, 0.232 0.459, 0.283
Refinement statistics
Resolution 50–3.5 35–1.26 35–1.78
Highest shell (A) 3.59–3.50 1.30–1.27f 1.88–1.78f
No. reflections 48 689 64 902 23 389
Rwork/Rfree
c 26.8/28.7 13.0/17.5 21.0/24.4
Highest shell 30.4/35.6 20.9/30.7 32.1/33.3
No. atomse 7589 2495 (2328) 2378 (2325)
Protein 7540 2251 (2086) 2135 (2082)
Ligand/ion 49 40 6
Solvent 0 220 (218) 237
Rmsd
Bond lengths (A) 0.009 0.010 0.023
Bond angles () 1.2 1.2 1.8
Ramachandran
Allowed region (%) 100.0 100.0 100.0
Favored region (%) 93.56 97.5 97.4
Molprobity clashscore 6 3.6 4.1
a The native data contain Zn2+ anomalous scatterers, but have been collected at a wavelength remote from the absorption peak.
b Data for the lowest and highest resolution shells are shown in parentheses. The completeness for the data for the lowest shell and full
resolution is calculated versus the number of possible reflections from infinity to the stated high-resolution limit.
c Data for the highest resolution shells are shown in parentheses.
d The twin component was not substantial enough to be used in the refinement (not to reduce the data to parameter ratio).
e Alternative conformations counted separately (the true number of atoms is shown in parentheses).
f Shells adjusted so that they include an Rfree reflection shell.
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forming a roof above the active site oriented towards
the middle of the groove. This loop and loops 3
and 4 have fairly similar conformations in all lysosta-
phin molecules in the three crystal forms. By
contrast, the smaller loop 2 seems to be the most
flexible (Fig. 6).
Zn2+ coordination cannot be deduced with confi-
dence for the mature lysostaphin structure, because of
the limited resolution. Metal–ligand distance restric-
tions had to be imposed so that the zinc density does
not dominate the positions of the lighter atoms. In one
subunit, we tentatively modeled a sulfate ion (from the
buffer) directly coordinating the Zn2+ ion. By con-
trast, the structures of the catalytic domain are very
informative in this respect. In crystals grown in the
absence of phosphate ions, we observed a hexa-coordi-
nated Zn2+ ion in the active site, with the expected
three amino acid ligands (His279, Asp283 and His362)
and three water molecules, in a nearly perfect octa-
hedral arrangement. In crystals grown in the presence
of phosphate, the Zn2+ amino acid ligands are
arranged similarly, but instead of the water molecules,
a phosphate ion is directly coordinated to the Zn2+
ion. Two of the phosphate oxygen atoms are roughly
in the positions previously occupied by water mole-
cules (although the oxygen–oxygen distance is shorter
for the phosphate than for the two water molecule
oxygens). Such coordination is not unusual for Zn2+
coordination by bidentate ligand atoms [28], and has
also been described for LytM [19] (Fig. 5).
Tetracoordination of the Zn2+ ion is typical for
most LAS enzyme crystal structures, but the Zn2+ ion
in LasA from P. aeruginosa is pentacoordinated [21].
Pentacoordination is consistent with many proposals
for catalytic mechanism, and also with EPR data for a
Co2+-substituted VanX (an enzyme that belongs to
the LAS superfamily, but not to metallopeptidase clan
M23) [29]. To our knowledge, hexacoordination with
only amino acid and water (hydroxide) ligands has so
far not been observed for any other LAS enzyme. Dif-
ferences in coordination state may reflect variations
between LAS family members, but more likely they
simply reflect the low energy barriers for changes of
Zn2+ coordination [30], which may also play a role in
catalysis [31].
CWT domain
The CWT domain of lysostaphin is highly similar in
sequence (> 80% identity) and structure to the CWT
of Ale-1 [20] (main chain atom rmsd 0.5 A). Biochemi-
cal and structural studies indicate that this domain
interacts directly with interpeptide bridges present in
peptidoglycans [32]. The fold classifies the domain as
SH3b, the prokaryotic counterpart of the eukaryotic
SH3 domain [33]. At present, structural information
A B C
Fig. 4. Sequence conservation and electrostatics of lysostaphin. The solvent-excluded surface of (A) catalytic and (B) CWT lysostaphin
domain was colored according to the sequence conservation determined using the Consurf server [55] , with a set of sequences selected
for analogous function and possibly diverse sequence (UniProt codes: H0DEX1, Q4L983, D3X7N2, F0P463, I7IJS5, I7JXS6, O05156,
J9GY33, J9GX22, D6A2X0, Q99WV0, Q99X10, G5JF40, K9AV95, K0TTI9, K0UDK3 for catalytic domain; and D3X7N2, Q99WV0, O05156,
H0DJE6, B9CV69, D3QFD1, J0GU31, H3UFQ3, D4FI37, Q4L3Y5, H9A141, F9L8Y9, E5CSC2, O56788 for the CWT domain). (C) Solvent-
accessible surface of lysostaphin colored according to the electrostatic potential calculated with the DELPHI program [56]. The orientation in
the top row is rotated 90° with respect the yellow/green molecule in Fig. 3 (and similar to Fig. 7A), the location of the putative substrate-
binding grooves is marked by arrows.
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on how the lysostaphin/Ale-1 family of CWT domains
interacts with substrates is rather limited, as neither
this work nor prior experiments with Ale-1 succeeded
in crystallizing a CWT with bound substrate. Never-
theless, some informed speculation is possible. Based
on a combination of structural studies, site-directed
mutagenesis experiments and computational docking,
amino acid residues of Ale-1 that affect peptidoglycan
binding have been identified [20,34]. Because of the
high sequence and structural similarity between the
lysostaphin and Ale-1 CWT domains, the equivalent
amino acids in the lysostaphin structure can be readily
identified and located. Together, they indicate a rela-
tively wide peptidoglycan-binding site, with notable
A B C
Fig. 6. Lysostaphin, LytM and LasA active site clefts. Internal variability of the loops surrounding the active sites of (A) lysostaphin, (B)
LytM and (C) LasA as captured by multiple molecules in the asymmetric units of their different crystal forms. The numbering of the loops
follows the nomenclature of Spencer et al. [21] The diameter of the ‘tubes’ and the color scheme correspond to the magnitude of the
residual temperature factors ranging from blue (low) to red (high).
A B C
D E F
Fig. 5. Catalytic sites of lysostaphin and related enzymes. (A) Active sites in the crystals of mature lysostaphin, the catalytic domain crystals
were grown in either the absence (B) or presence (C) of phosphate; (D) active LytM and (E) LasA (previously characterized closely related
peptidases). (F) Metal–ligand distances (in A) for (A–E). The low resolution makes interpretation of the density in (A) very tentative. The
distances shown in (E) differ between molecules in the asymmetric unit for all presented structures. The electron-density maps shown in
cyan in are composite omit maps contoured at 1.5 rmsd. The maps shown in magenta are Bijvoet-difference Fourier (anomalous scattering
density) maps calculated with the phases from the final models depleted of Zn2+ ions, and contoured at 6 rmsd.
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enrichment of binding-related residues in the central
groove of the domain (Fig. 7).
Different linker conformations, domain mobility
Comparison of the four lysostaphin molecules in the
asymmetric unit of the crystals using the DynDom ser-
ver [35] shows that they can be divided into pairs of
molecules of very similar overall structure. However,
between the pairs, there is major variation in the rela-
tive domain orientation, because of differences in the
linker conformation around Gly388. The local differ-
ences in the linkers have drastic overall consequences.
When CWT domains are superimposed, the catalytic
domain orientations differ by ~ 100° and active sites
are up to ~ 25 A from each other (Fig. 3). The linker
amino acid composition in lysostaphin (rich in gly-
cines) classifies the linker as flexible [36]. Moreover,
analysis of the amino acid conservation among lysosta-
phin and those homologues that share the architecture
of N-terminal catalytic and C-terminal CWT domain
reveals that the linker is among the least conserved
regions of the proteins (conservation is even lower in
the proregions).
Biochemical data suggest that domain mobility in
solution exceeds the range observed in the crystal
structure. Experimentally introduced cysteines in posi-
tions 332 (K332C) and 464 (T464C) can be cross-
linked under oxidizing conditions [12], but the Ca car-
bon atoms of the mutated residues are > 45 A apart in
all four molecules in the structure and cannot even be
approximated by a simple closure or hinge between
lysostaphin domains (Fig. 7A).
Possible interactions between the catalytic and CWT
domains of lysostaphin were previously studied by
comparing exposure to hydrogen/deuterium exchange
between the full-length protein and its isolated
domains [12]. In light of the structural data, the
reported greater exposure of peptide 248–260 for the
isolated domains is expected, because these residues
are partly covered by the linker not included in the
constructs for individual domains. Peptides 331–339
(on the surface of the catalytic domain) and 454–473
and 474–488 (in the CWT, partly in regular b-struc-
ture, but also containing surface exposed loops and
edge strand fragments) are not in contact with the
other domain in any of the four molecules in the crys-
tal. Changes in their exposure to solvent between
domains and full-length enzyme therefore require
domain arrangements not observed in the structure, or
alternatively ‘interdomain communication’ (Fig. 7A).
The above observations suggest that lysostaphin may
anchor itself to peptidoglycan via its CWT domain,
which could then cleave different interpeptides in the
region, thus locally weakening peptidoglycan in a more
effective way than by random cleavages throughout the
polymer. The precise number of S. aureus interpeptide
cross-bridges is unfortunately difficult to estimate,
because the peptidoglycan structure is uncertain and
because ‘parallel stem peptide’ models predict closer
packing of cross-bridges than ‘antiparallel stem peptide’
models. We note that a modular architecture of
peptidoglycan hydrolases is fairly common [37–40],
particularly in phage from Gram-positive bacteria,
which also need to keep lysis local [41,42]. The benefit
from tethering a catalytic domain to a CWT domain is
nicely illustrated by grafts of CWT domains to unre-
lated peptidoglycan hydrolases [43] and may at least in
part explain the superiority of lysostaphin over LytM in
in vivo applications.
A B
Fig. 7. Mapping of residues implicated in interdomain contact and peptidoglycan binding onto the lysostaphin structure. (A) Full-length
lysostaphin structure in ribbon representation. Peptides that show a hydrogen/deuterium effect because of domain interaction are
highlighted in red. The Ca atoms of residues that were replaced with cysteines and were cross-linked are shown as red balls [12]. The
catalytic and CWT domains are shown in yellow and green, the flexible linker is in brown. (B) Surface representation of lysostaphin CWT
domain. Lysostaphin counterparts of residues identified as responsible for substrate binding in Ale-1 by Lu et al. [20] and Hirakawa et al.
[34] are shown in pink and blue, the residues identified by both studies are shown in magenta. The orientation of the CWT domain in the
left-hand panel of (B) is analogous to that in (A).
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Experimental procedures
Protein purification
The expression plasmid for lysostaphin (pET21) encoded
the catalytic and CWT domains (residues 248–493, UniProt
entry P10547) and a C-terminal His-tag (LEHHHHHH
sequence) under the control of the T7 promoter and lac
repressor, as described previously [44]. BL21(DE3) Escheri-
chia coli cells were grown in 29 YT media to a D600 of 0.6,
induced with 1.2 mM isopropyl b-D-thiogalactoside, and
grown for a further 3 h at 30 °C. The collected cells were
harvested and the lysate was used for protein purification.
The first purification step was performed on a Zn2+ col-
umn (5 mL Pharmacia HiTRAP chelating column charged
with 50 mM ZnCl2). The imidazole gradient was run from
5 mM to 1 M in 20 mM sodium phosphate pH 7.0, 0.5 M
NaCl. Histidine-tagged lysostaphin eluted at 0.3–0.4 M
imidazole. Gel filtration on a Sephacryl S100 column in
20 mM Tris/HCl pH 7.0, 0.5 M NaCl, 0.2 M imidazole was
done as the final step of protein purification. After gel fil-
tration, the protein sample was dialyzed against 20 mM
Tris/HCl pH 7.0, 50 mM NaCl and concentrated.
The lysostaphin catalytic domain (residues 251–384) was
cloned into the NcoI/XhoI site of a pET15b plasmid. The
134 amino acid peptide was overproduced in BL21 (DE3)
E. coli in Luria–Bertani media by induction with 0.1 mM
isopropyl b-D-thiogalactoside at 25 °C for 6 h. The cell pel-
let was suspended in 20 mM Tris/HCl pH 7.0, 1 M NaCl,
10% glycerol and disrupted by Constant Cell Disruption
System (Constant Systems Ltd, Daventry, UK). Cell lysate
was dialyzed against 20 mM Tris/HCl, pH 7.0, 50 mM NaCl
and purified on SP Sepharose column (GE Healthcare,
Uppsala, Sweden). The NaCl gradient was applied and the
protein was eluted at ~ 0.9 M NaCl. Further purification
was done by gel filtration on Superdex 75 column (GE
Healthcare) in dialysis buffer.
Crystallization
All crystallization experiments were carried out by the
vapor diffusion method in sitting drops at 4 °C. Mature
lysostaphin was concentrated to 8 mgmL1, and mixed in
a 1 : 1 ratio with the reservoir buffer containing 0.1 M
Mes/NaOH pH 6.5 and 1.6 M magnesium sulfate and
2 mM tetraglycine phosphinic acid. Drops were then equili-
brated against the reservoir buffer. EDTA and ammonium
sulfate as additives improved crystal quality. Prior to flash-
cryocooling, the crystallization buffer was supplemented
with 25% (v/v) glycerol. Lysostaphin crystals belonged to
the cubic space group P4(3)32 and diffracted to 3.5–4 A
resolution at synchrotron beamlines.
Crystals of the catalytic domain of lysostaphin in the
absence of phosphate were grown within a month by mix-
ing an 11.5 mgmL1 solution of the protein in a 1 : 1 ratio
with reservoir buffer Morpheus 2-46 (Molecular Dimen-
sions, Newmarket, UK). This buffer is composed of 0.1 M
Tris (base), Bicine pH 8.5, 0.1 M amino acids [L-Na-gluta-
mate, alanine (racemic), glycine; lysine-HCl (racemic); ser-
ine (racemic)], 30% v/v precipitant (ethylene glycol,
PEG 8000). Crystals grew during a month of equilibration
against the reservoir buffer. Crystals were flash-cooled
directly from the drop. Thirty minutes prior to setting up
the crystallization trials, the protein had been supplemented
with 6 mM of the pentapeptide GGSGG, which should be
resistant to lysostaphin cleavage because of the presence of
the serine residue. However, there was no electron density
for the pentapeptide found in the crystal.
Crystals of the catalytic domain of lysostaphin in the pres-
ence of phosphate were obtained by mixing the protein solu-
tion at a concentration of 11.5 mgmL1 in a 1 : 1 ratio with
the reservoir buffer Structure Screen 1–46 (Molecular
Dimensions) containing 0.05 M potassium dihydrogen phos-
phate and 20% w/v PEG 8000. Similarly as in the absence
of phosphates, the crystals grew within a month. Prior to
flash-cryocooling, the crystallization buffer was supple-
mented with 10% (v/v) glycerol. Thirty minutes prior to set-
ting up the crystallization trials, the protein had been
supplemented with 6 mM glycine hydroxamate. Crystals
were soaked for 5 min with 25 mM iodo-GGSGG pentapep-
tide dissolved in the buffer used for cryocooling, but no elec-
tron density for the putative inhibitors was observed.
Structure determination
The crystals of the full-length lysostaphin were tested on
multiple beamlines (of DIAMOND, ELETTRA, PETRA
and BESSY) aiming at the highest possible data quality.
The best dataset was collected on the MX 14.1 beamline of
BESSY at a wavelength of 0.9184 A. Two wavelength
MAD data that have been used for phasing were collected
on DIAMOND IO2 beamline to 4.0 A. The two final data-
sets for the lysostaphin catalytic domain were collected at
MX 14.1 (1.26 A) and 14.2 (1.78 A). All diffraction data
were processed using the XDS suite [45].
The full-length lysostaphin structure was solved by a
combination of the molecular replacement (MR) and the
MAD methods. Careful preparation of the search models
proved crucial. Multiple structure-based sequence align-
ments were generated for the homologues of the catalytic
and CWT domains of lysostaphin, using the DALI sever
[46]. The alignments revealed potential flexible loop regions
(indicated by high rmsd values and high crystallographic
temperature factors), which were deleted for the MR
search. Finally, the structures of S. aureus LytM (PDB ID
2B0P, chain A [19]) and S. capitis Ale-1 (1R77, chain A
[20]) were chosen as search models based on the low overall
temperature factors and high resolution. A sequential MR
search scheme was carried out using PHASER [47]. The first
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three copies of the truncated LytM search model were
placed correctly with high log likelihood gain values. Place-
ment of three copies of truncated Ale-1 in subsequent MR
search steps raised the log likelihood gain value of the solu-
tion to over 1000. Placement of further molecules by MR
failed. Therefore, a two-wavelength MAD experiment (peak
wavelength 1.2827 A and inflection wavelength 1.2831 A)
was performed to obtain experimental phases. Zn2+-bind-
ing sites were located in the anomalous difference Fourier
map calculated with peak wavelength diffraction data and
model phases. Altogether, only four Zn2+ ions were found,
strongly suggesting that the crystals contained four mole-
cules of lysostaphin in the asymmetric unit. The programs
SHARP [48] and SOLOMON [49] were used to calculate an
experimental electron-density map, which was very clear
even without noncrystallographic symmetry averaging. The
two missing domains (one catalytic and one CWT) were
tentatively built by manual density interpretation. Electron
density was then cut out in their vicinity and used for addi-
tional real-space MOLREP [50] searches using the models of
the catalytic and CWT domains. The linkers between cell
wall and catalytic domain were built manually with the
COOT program [51]. Register errors are very unlikely in the
globular domains and the better defined parts of the link-
ers. In all four cases, the electron density is of sufficient
quality to decide with confidence which catalytic and CWT
domains are covalently linked. In the most ill-defined
regions of the linkers, Ramachandran indicators suggest
that the model is poorer than elsewhere, and we cannot
exclude register errors. Refinement of the mature lysosta-
phin was carried out in REFMAC [52] with separate noncrys-
tallographic symmetry restraints for CWT (residues
403–493) and catalytic (residues 278–385) domains, but no
noncrystallographic symmetry restraints for the linkers
(386–402). The model was refined to the final R-factors of
Rcryst = 27.8% and Rfree = 29.6%. Geometry indicators of
the model were typical of structures at this resolution (rmsd
bond lengths = 0.012 A, rmsd angles = 1.4°, 99.3% of resi-
dues in the allowed region of the Ramachandran plot).
The crystals of the lysostaphin catalytic domain had a
nearly orthorhombic lattice. However, scaling of the dif-
fraction data indicated that the crystals were only mono-
clinic. Extinctions on the axis of symmetry identified the
space group as P2(1). An analysis of the solvent content
suggested the presence of two catalytic domains in the crys-
tallographic asymmetric unit. The crystal grown in the
presence of phosphate showed clear indications of twinning
and thus test reflections were selected in thin resolution
shells. The structure was solved by MR with the help of
the catalytic domain of the mature enzyme. The model was
rebuilt automatically with the ARP/WARP program [53]. The
structure was refined with PHENIX [54] in the twin refine-
ment mode, which reduced the R factors by ~ 7%. The
crystal grown in the absence of phosphate was solved with
MR using the refined catalytic domain structure as a
model. The test reflections were chosen consistently. The
crystal was did not appear to be significantly twinned, as
judged by XTRIAGE [54], therefore the refinement was carried
out in the standard mode in REFMAC [52]. Data collection
and refinement statistics are presented in Table 1. The
atomic coordinates and corresponding structure factors
have been deposited at PDB with the following accession
codes: full-length lysostaphin, 4LXC; catalytic domain in
the presence of the phosphate, 4QP5; and in its absence,
4PQB.
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